PB 94 of 2017
I, LISA LA RANCE, Assistant Secretary, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.
Dated 28th November 2017
LISA LA RANCE
Assistant Secretary
Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health
___________________________________________________________________________
Amendment instrument – Pharmaceutical benefits – early supply
1 Name of Instrument
(1) This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2017 (No. 9)
(2) This Instrument may also be cited as PB 94 of 2017.
2 Commencement
This Instrument commences on 1 December 2017.
3 Amendment of PB 120 of 2015
Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).
Schedule 1 Amendments
[1] Schedule 1, after entry for Abiraterone
insert:
Abiraterone | Tablet containing abiraterone acetate 500 mg | 20 | 60 | 2 | |
[2] Schedule 1, entry for Atorvastatin and ezetimibe
omit:
Atorvastatin and ezetimibe | Pack containing 30 tablets atorvastatin 10 mg (as calcium) and 30 tablets ezetimibe 10 mg | 20 | 1 | 5 | |
Atorvastatin and ezetimibe | Pack containing 30 tablets atorvastatin 20 mg (as calcium) and 30 tablets ezetimibe 10 mg | 20 | 1 | 5 | |
Atorvastatin and ezetimibe | Pack containing 30 tablets atorvastatin 40 mg (as calcium) and 30 tablets ezetimibe 10 mg | 20 | 1 | 5 | |
Atorvastatin and ezetimibe | Pack containing 30 tablets atorvastatin 80 mg (as calcium) and 30 tablets ezetimibe 10 mg | 20 | 1 | 5 | |
[3] Schedule 1, entry for Auranofin
omit:
Auranofin | Tablet 3 mg | 20 | 100 | 3 | |
[4] Schedule 1, after entry for Ibandronic acid
insert:
Ibrutinib | Capsule 140 mg | 20 | 90 | 5 | |
[5] Schedule 1, after entry for Mesalazine in the form Tablet 500 mg (prolonged release)
insert:
Mesalazine | Tablet 800 mg (enteric coated) | 20 | 180 | 5 | |
[6] Schedule 1, entry for Tenofovir with emtricitabine, elvitegravir and cobicistat
omit:
Tenofovir with emtricitabine, elvitegravir and cobicistat | Tablet containing tenofovir alafenamide 10 mg with emtricitabine 200 mg, elvitegravir 150 mg and cobicistat 150 mg | 20 | 60 | 5 | |
[7] Schedule 1, after entry for Umeclidinium with vilanterol
insert:
Ustekinumab | Injection 45 mg in 0.5 mL | 20 | 1 | 1 | |